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ABSTRACT
Middle East respiratory syndrome coronavirus (MERS-CoV) is a WHO priority pathogen for which vaccines are urgently
needed. Using an immune-focusing approach, we created self-assembling particles multivalently displaying critical
regions of the MERS-CoV spike protein ─fusion peptide, heptad repeat 2, and receptor binding domain (RBD) ─ and
tested their immunogenicity and protective capacity in rabbits. Using a “plug-and-display” SpyTag/SpyCatcher system,
we coupled RBD to lumazine synthase (LS) particles producing multimeric RBD-presenting particles (RBD-LS). RBD-LS
vaccination induced antibody responses of high magnitude and quality (avidity, MERS-CoV neutralizing capacity, and
mucosal immunity) with cross-clade neutralization. The antibody responses were associated with blocking viral
replication and upper and lower respiratory tract protection against MERS-CoV infection in rabbits. This arrayed
multivalent presentation of the viral RBD using the antigen-SpyTag/LS-SpyCatcher is a promising MERS-CoV vaccine
candidate and this platform may be applied for the rapid development of vaccines against other emerging viruses
such as SARS-CoV-2.
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Introduction
Emerging zoonotic viruses, such as severe acute respir-
atory syndrome coronavirus (SARS-CoV) and Middle
East respiratory syndrome coronavirus (MERS-CoV)
have been able to cross the species barrier posing a
threat to the human population. MERS-CoV causes
severe respiratory disease and fatalities in humans
[1,2], and the virus is continuously introduced into
the human population through infected dromedary
camels, the viral reservoir with resulting outbreaks
[3]. The wide geographical distribution of this viral
reservoir, the high case-fatality rate in humans (35%),
and the lack of treatment and licensed vaccines, make
the virus a threat to the human population. This has
put MERS-CoV on the recent WHO list of diseases
having an epidemic or even pandemic potential for
which countermeasures are lacking and are urgently
needed [4].
Vaccination is potentially one of the most effective
ways to prevent the ongoing MERS-CoV outbreaks.
Several MERS-CoV vaccine candidates have been
developed using different platforms including
inactivated, live-attenuated, and subunit vaccines [5].
Compared to other vaccine production platforms,
recombinant subunit proteins have a higher safety
profile, are relatively faster and easier to produce, and
can be scaled-up in a more cost-effective manner;
nonetheless, they tend to induce lower levels of protec-
tive immunity [6]. The use of self-assembling multi-
meric protein scaffold particles (MPSP) to present
antigens in a multivalent virus-mimicking manner
(size, repetitiveness, and geometry), has been shown
to enhance vaccine-induced immune responses [7–
11], and to offer advantages over other multimeric anti-
gen presentation platforms (reviewed in [12]). Both
lumazine synthase (LS) and I3-01 (I3) can self-assem-
ble into 60-meric particles, which can be expressed in
E. coli and have been used as scaffolds for development
of multimeric vaccines with improved immune
responses compared to monomeric forms [13–15].
An LS-based HIV vaccine, (eOD-GT8), has recently
advanced to a phase I human clinical trial
(NCT03547245). Linking of antigens to these MPSP
can be achieved through several mechanisms; as e.g.
genetic fusion or the SypTag-SpyCatcher (ST/SC)
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system [16]. While the former requires the antigen and
scaffold to be produced in the same expression system,
the latter allows each to be expressed in its suitable sys-
tem harnessing a rapid post-translational “plug-and-
play” assembly. This is advantageous, allowing
scaffold-SC to be produced at scalable levels in E. coli
and SpyTagged glycosylated antigens such as viral sur-
face proteins to be produced in its optimal system, such
as mammalian or insect cells. The antigen-ST can then
be multivalently displayed on the surface of the SC-
scaffolds through the spontaneous formation of a stable
isopeptide bond. This can be a platform for rapid vac-
cine manufacturing in case of epidemics or pandemics,
to create optimized vaccines at reduced costs and also
with reduced development times.
The MERS-CoV spike (S) protein is the main target
for subunit vaccine development [5] It assembles as a
homotrimer and consists of an N-terminal head (S1
subunit) and a C-terminal stalk (S2 subunit). The S1
subunit mediates virus attachment and entry through
its N-terminal S1A domain and its C-terminal receptor
binding domain (RBD), respectively [17,18]. The S1A
domain binds sialic acids, a viral attachment factor,
while the RBD binds to the viral receptor, dipeptidyl
peptidase 4 (DPP4). Following attachment and
entry, the S2 subunit mediates viral fusion to the
host cell through its fusion machinery; comprised of
the fusion peptide (FP) and the two heptad repeats
– HR1 and HR2 [19]. MERS-CoV neutralizing anti-
bodies (Abs) mainly recognize epitopes in the RBD
of the spike head S1 subunit; and to a lower extent,
epitopes in the sialic acid binding domain and the
fusion-mediating more conserved S stalk (S2). None-
theless, antibodies directed against the sialic acid bind-
ing S1A domain or the more conserved S2 subunit,
although subdominant, may protect against MERS-
CoV [20,21].
Immune focusing can enhance immune responses
to subdominant regions [22]. In the current study,
using LS and I3 self-assembling particles, we evaluated
whether immune focusing and multivalent presen-
tation can induce immune responses to the more
sequence-conserved S2 regions: FP and HR2. Further-
more, using a SypTag/SpyCatcher system and LS par-
ticles, we tested whether immune focusing with/
without multivalent presentation of the viral RBD
can lead to enhanced protection against a MERS-
CoV challenge in rabbits.
Materials and methods
Protein design and expression
Expression constructs were cloned using standard PCR
methods. The gene encoding the 6,7-dimethyl-8-ribi-
tyllumazine synthase (LS; GenBank accession no.
WP_010880027.1) of A. aeolicus was synthesized
using human-preferred codons obtained from Gen-
Script USA, Inc, as described previously [17]. The
cysteine at position 37 and asparagine at position 102
of LS were mutated to alanine and glutamine, respect-
ively. The gene encoding I3-01 (I3; PDB 5KP9, amino
acid residues 19–222) derived from Thermotoga mari-
tima was synthesized using human-preferred codons
obtained from GenScript USA. The gene fragments
encoding the ΔN1SpyCatcher (SC; UniProt accession
no. AFD50637.1; amino acid residues 48–139; [23])
and SpyTag (ST; UniProt accession no.
WP_129284416.1; amino acid residues 981–994)
based on the Cna B-type domain-containing protein
of Streptococcus pyogenes were synthesized using
human-preferred codons obtained from GenScript
USA, Inc. The LS and I3 gene constructs were cloned
into the pGEX-2 T bacterial expression vector (Sigma
Aldrich).
To generate the HR2-LS expression vector, the
HR2 region (amino acid residues 1215–1287) encod-
ing sequence of the MERS-CoV S gene (accession no.
NC_019843) was ligated in-frame with an N-terminal
sequence encoding a CD5 signal sequence and strep-
tag tag purification tag, and with a C-terminal
sequence encoding the LS via a linker, and sub-
sequent cloned into the pCAGGS mammalian
expression vector.
To generate the I3-HR2 expression vector, the hep-
tad repeat 2 encoding region (HR2, amino acid resi-
dues 1215–1287) of the MERS-CoV S gene was
ligated in-frame with an N-terminal sequence encoding
the I3-01 and a C-terminal streptag purification tag
interspaced with a linker, and subsequent cloned into
the pGEX-2 T bacterial expression vector (Sigma
Aldrich).
To generate the FP-I3 and FP-LS expression vectors,
the fusion peptide (FP; amino acid residues 884–898)
encoding sequence of the MERS-CoV S gene was
ligated in-frame with an N-terminal sequence encoding
the I3-01 or LS, and a C-terminal Streptag purification
tag and subsequently cloned into the pGEX-2 T bac-
terial expression vector (Sigma Aldrich).
To generate the RBD-ST expression vector, the
MERS-RBD (amino acid residues 358–588) encoding
sequence of the MERS-CoV S gene was ligated in-
frame with an N-terminal sequence encoding a CD5
signal sequence and with a C-terminal sequence encod-
ing the ST followed by a double Streptag, and sub-
sequently cloned into the pCAGGS mammalian
expression vector.
To generate the LS-SC expression vector, the codon
optimized SC sequence equipped with an N-terminal
FLAG-tag (DYKDDDDK) was cloned to the N-termi-
nus of the LS sequence in the pET15b bacterial
expression vector (Novagen).
All protein sequences are provided in Supplemen-
tary Figures S1 and S2.
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Mammalian expression
Mammalian expression of the HR2-LS and RBD-ST
constructs was done, as described previously [17]. In
short, expression plasmids were polyethylenimine
(PEI)-transfected into 60% confluent HEK-293 T cells
for 6 h, after which transfections were removed and
medium was replaced with 293 SFM II-based
expression medium (Gibco Life Technologies) and
incubated at 37 °C in 5% CO2. Tissue culture super-
natants were harvested 5–6 d post transfection, and
expressed proteins were purified using StrepTactin
Sepharose beads (IBA) according to the manufacturer’s
instruction.
Bacterial protein expression
BL21 cells (Novagen) were transformed with pGEX-
2 T expression vectors and grown in 2× yeast-tryptone
medium to log phase (OD600 ∼1.0) and subsequently
induced by adding IPTG (isopropyl-β-d-thiogalacto-
pyranoside) (GIBCO BRL) to a final concentration of
1 mM. Two hours later, the cells were pelleted, resus-
pended in 1/25 volume of 10 mM Tris (pH 8.0)-
10 mM EDTA-1 mM phenylmethylsulfonyl fluoride,
and sonicated on ice (five times, 2 min each). The
cell homogenates were centrifuged at 20,000 × g for
60 min at 4°C. Proteins were purified from the cell
lysate supernatant using StrepTactin Sepharose beads
(IBA) according to the manufacturer’s instruction.
All purified proteins were analyzed on a 12% SDS/
PAGE gel under reducing conditions and stained
with GelCodeBlue stain reagent (Thermo Scientific).
Purified proteins were stored at 4°C until further use.
Expression of the FLAG-LS-SC was performed as
described above with the following modifications: 1)
Cells were treated with 1 mg/ml lysozyme in lysis
buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton
X-100) for 1 h at room temperature prior to sonifi-
cation on ice. 2) Purification was performed using
ANTI-FLAG® M2 Affinity Gel (Sigma Aldrich) as rec-
ommended by the manufacturer. Purified proteins
were dialyzed against 1x TBS buffer (50 mM Tris-
HCl, 150 mM NaCl, pH 7.4) and stored at −80°C
until further use.
Rabbit immunizations
Rabbit immunizations and challenge were carried out
at Viroclinics Bioscience B.V. under permit no.
AVD277002015283-WP03, using BSL-3 containment
facilities. Female New Zealand White rabbits (Envigo,
Venray, the Netherlands) of 11 weeks age were
assigned to six groups (i-vi) of five animals each.
Immunizations were performed intramuscularly with
either i) HR2-LS, ii) FP-LS, iii) LS, at day 0 and boosted
with either i) HR2-I3, ii) FP-I3, iii) I3 on day28 or iv)
PBS, v) RBD + LS, vi) RBD-LS on days 0 and 28. Each
animal received each time 15 µg of antigen adjuvanted
with Adjuplex (5%; Sigma-Aldrich, Zwijndrecht, the
Netherlands) in a total volume of 500 µL. Three
weeks after the last vaccination (day 49 of the study),
all animals were challenged intranasally under anesthe-
sia with MERS-CoV (106 50% tissue culture infectious
dose (TCID50) MERS-CoV EMC strain (accession no.
NC_019843) in a volume of 1 mL divided over both
nostrils). The animals were euthanized on day 4 post-
challenge (day 53 of the study). Serum samples were
collected on days 0, 28, and 46. Nasal swabs were col-
lected on day 46 (pre-challenge) and on days 1 through
4 post-challenge. Following euthanasia, lungs were
examined for gross pathology and lung tissue samples
were collected for virus detection, and in 10% formalin
histopathology and immunohistochemistry.
Enzyme-linked immunosorbent assay (ELISA)
Antigen-binding and anti-LS (scaffold) antibodies pro-
duced after vaccination were tested in the sera collected
at different time points as well as in pre-challenge nasal
swabs using ELISA. Costar high-binding 96-well
ELISA plates were coated overnight at 4°C with 1 µg/
ml of either recombinant LS, MERS-CoV S1 or S2 pro-
teins in PBS. The plates were washed with PBS and
blocked for 1 hr using 1%BSA/0.5%Tween-20/PBS.
Following blocking, diluted samples (1:100 or serially
diluted) were added and further incubated for 1 hr.
The plates were then washed and and probed with an
HRP-labeled goat anti-rabbit Ig (1:2000, Dako) sec-
ondary antibody. TMB was used for signal develop-
ment and the absorbance of each sample was
measured at 450 nm (OD450).
Antibody avidity ELISA
Antibody avidity was assessed using an ammonium
thiocyanate (NH4SCN)-displacement ELISA. This
was carried out as described above using serum
dilutions containing same level of S1 absorbance
units added in triplicates. Following serum incubation
and washing, NH4SCN (0–5 M) was added to the wells
for 15 min. The plates were then washed and further
developed as described above. The concentration of
NH4SCN resulting in a 50% reduction in signal was
taken as the avidity index (IC50).
ELISA analysis of immunogen binding by
antibodies
To confirm the antigenicity of the RBD-LS particles, we
tested its binding to well-characterized monoclonal
antibodies binding conformational RBD epitopes
[20]. Human monoclonal antibodies 7.7G6, 1.6F9,
1.2G5, 1.8E5, 4.6E10 targeting the receptor binding
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domain of the MERS-CoV spike protein were pro-
duced and purified as described earlier [20]. NUNC
Maxisorp plates (Thermo Scientific) were coated with
the RBD-LS antigen at 100 ng /well at 4°C overnight.
Plates were washed three times with PBS containing
0.05% Tween-20 and blocked with PBS with 5% Proti-
far in PBS containing 0.1% Tween-20 at room temp-
erature for 2 h. Four-folds serial dilutions of mAbs
starting at 10 µg/ml (diluted in blocking buffer) were
added and plates were incubated for 1 h at room temp-
erature. Plates were washed three times and incubated
with HRP-conjugated goat anti-human secondary anti-
body (ITK Southern Biotech) diluted 1:2000 in block-
ing buffer for one hour at room temperature. HRP
activity was measured at 450 nm using tetramethylben-
zidine substrate (BioFX) and an ELISA plate reader
(EL-808, Biotek).
Plaque reduction neutralization assay
The presence of MERS-CoV neutralizing antibodies in
the sera and nasal swabs of vaccinated animals was
tested using a plaque reduction neutralization assay
(PRNT). Heat –inactivated two-fold serially diluted
samples (starting 1:10) were mixed 1:1 with 400 PFU
of MERS-CoV (EMC/2012) and incubated for one
hour. The mix was then overlaid on HuH-7 cells in
96-well plates. Following one hour of incubation, the
mix was removed and the cells were incubated for
8 hr. The cells were then fixed, permeabilized and
stained using a mouse anti-MERS-CoV N protein
monoclonal antibody (Sino Biological) followed by an
HRP-labelled goat anti-mouse IgG1 (SouthernBio-
tech). The signal was developed using a precipitate
forming peroxidase substrate (True Blue, KPL). The
ImmunoSpot® Image analyzer (CTL Europe GmbH)
was used to count the number of infected cells per
well. The neutralization titre of each serum sample
was determined as the reciprocal of the highest dilution
resulting in a ≥50% (PRNT50) or ≥90% (PRNT90)
reduction in the number of infected cells. A titre
of≥ 20 was considered to be positive.
Viral RNA detection
To evaluate the protective efficacy of vaccination
against MERS-CoV challenge, nasal swabs, and hom-
ogenated lung tissues were tested for the presence of
MERS-CoV RNA using RT-qPCR for and for the pres-
ence of infectious virus by virus titration.
The presence of viral RNA in nasal swabs and lung
tissues was tested using UpE RT-qPCR as previously
described [24]. RNA was extracted from samples
using Magnapure LC total nucleic acid isolation kit
(Roche). RNA amplification and quantification were
carried out using a 7500 Real-Time PCR System
(Applied biosystems). Samples with a Ct value <40
were considered positive. RNA dilutions extracted
from a MERS-CoV stock of known titre was used to
generate a standard curve in order to calculate the
TCID50 equivalent of RNA detected in samples. Con-
centrations of viral RNA in lung tissue are expressed
in as TCID50 equivalents per gram tissue (TCID50 eq/
g), and in the nasal swabs as TCID50 eq/mL.
Virus titration
The presence of MERS-CoV infectious viral particles in
respiratory tract samples (nasal swabs and lung tissue
homogenates) was detected by titration on Vero cells
as described previously [24]. Briefly, 10-fold serially
diluted samples (starting undiluted) were overlaid on
Vero cells and the plates were incubated for five days
at 37°C and the cytopathic effect was recorded. Infec-
tious virus titres in lung tissue are expressed as
TCID50 per gram tissue (TCID50/g), and infectious
virus titre in nose swabs are expressed as TCID50/mL.
Histopathology and immunohistochemistry
Lung tissue samples were collected in formalin and
embedded in paraffin for pathological analysis. Hema-
toxylin-eosin staining was carried out for histopatholo-
gical analysis. The presence of MERS-CoV
nucleoprotein was detected by immunohistochemistry
as previously published [24].
Statistical analysis
Statistical analyses were performed using Prism 7
(GraphPad Software Inc, USA). Data were compared
using Mann-Whitney U test or Student’s t-test. P-
values < 0.05 were considered significant.
Data availability
All data are available within the article and its sup-
plementary information or available from the authors
on request.
Results
Generation of MERS-CoV spike particles
Particulate multivalent antigen display can enhance
immunogenicity through different mechanisms, allow-
ing for induction of immune responses against other-
wise weakly immunogenic antigens [7,25]. We sought
to design antigens capable of inducing strong immune
responses against critical parts of the viral entry and
fusion machinery within the MERS-CoV spike protein
through immune focusing and multivalent presen-
tation on self-assembling particles (Figure 1). Within
the S1 subunit, the RBD is the main target for the
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induction of neutralizing antibodies and has been used
to develop several vaccine candidates for MERS-CoV
[5,26]. Indeed, the immunogenicity of RBD can be
enhanced by its presentation on ferritin nanoparticles
[27]. Likewise, the fusion peptide (FP) and the HR2,
which show a high degree of sequence conservation
among CoVs relative to the RBD, play crucial roles in
the CoV spike-mediated fusion machinery, and can
be targets for CoV protective antibodies [28–32]. Gen-
etic fusion was chosen for FP and HR2, due to their
small size, whereas the ST/SC system was used for
RBD display on particles to ensure correct folding of
the protein.
Two 60-meric hyperstable self-assembling particles
with icosahedral symmetry were used for multivalent
display of MERS-CoV domains. The lumazine
synthase (LS) particle, an icosahedron with a diameter
of 15 nm (PMID: 23539181) and the I3-01 (I3) particle,
a dodecahedron with a diameter of 25 nm (PMID:
27309817). The N- and C-termini of both scaffolds
are surface exposed, providing a platform to multiva-
lently present (antigenic) domains. Two functional seg-
ments of the S2 subunit of the MERS-CoV spike
protein were genetically fused to these nanoparticles;
the fusion peptide containing region (amino acid resi-
dues 884–898) and the HR2 containing region (amino
acid residues 1215–1287) (Figure 1B, Supplementary
Figure S1). Chimeric nanoparticles were purified after
expression in eukaryotic (mammalian) or prokaryotic
systems (Figure 1).
Generation of multimeric RBD-ST/LS-SC
(RBD-LS)
In addition, we used the SpyTag/SpyCatcher system to
multivalently display the MERS-CoV RBD on LS nano-
particle via covalent bonding [8]. For this purpose, the
SpyCatcher (SC) was genetically fused to LS and
expressed and purified from E. coli. The SpyTag (ST)
was genetically fused to the MERS-RBD (amino acid
Figure 1. Generation of multimeric protein scaffold particles (MPSP)- based vaccines used in this study. (A) Schematic diagram of
the MERS-CoV spike (S) protein mapping regions selected for vaccine generation; the receptor binding domain (RBD), the fusion
peptide (FP) and heptad repeat 2 (HR2). (B, C) Schematic diagram illustrating the construct design and production of the lumazine
synthase (LS) and I3-01 (I3)-based self-assembling MPSP vaccines. (D) Reducing SDS-PAGE showing generation of RBD-LS by
covalent coupling of RBD-SpyTag (RBD-ST) and LS-SpyCatcher (LS-SC) at different molar ratios of LS-SC: RBD-ST with the last
two lanes showing each in its free (uncoupled) form. (E) Reducing SDS-PAGE analysis of immunogens used in this study. The
size of each protein (KDa) is given in Supplementary Table S1. * Fuzzy bands due to heterogeneous glycosylation of HR2 or RBD.
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residues 358–588) and expressed and purified from
HEK-293 T cells (Figure 1C). RBD-ST was incubated
with LS-SC in different molar ratios to assess the opti-
mal coupling of both components. A 1:2 molar ratio of
RBD-ST and LS-SC allowed the optimal coupling of all
of the provided RBD-ST antigens to the SC-LS particles
(Figure 1D). The resulting conjugation products were
used for immunization. In order to assess the effect
of the particle-based multivalent antigen display on
immunogenicity, a mixture of non-coupled RBD-ST
and LS (without SC) was taken along for immunization
in the same molar ratio. All particulate preparations
displaying MERS-S antigenic domains (genetically
fused or SC/ST coupled) were analyzed by SDS-
PAGE (Figure 1E, Supplementary Table S1), confi-
rming their molecular integrity. We further confirmed
the antigenicity of the RBD-LS particles by testing their
capacity to bind monoclonal antibodies directed
against conformational epitopes on the RBD [20]
using ELISA. All antibodies bound to RBD-LS in a
dose dependant manner (Figure S3) indicating that
the RBD is correctly folded confirming its antigenicity.
Immunogenicity of particulate MERS-CoV spike
vaccines in rabbits
We then evaluated the immunogenicity of the multi-
meric spike antigens using six groups of rabbits (n =
5 per group), which were intramuscularly immunized
twice at a 4-week interval (Figure 2A). The LS/I3 and
PBS immunized groups served as controls.
After the first immunization, we detected antibody
responses against the corresponding S subunit (S1 or
S2) in the vaccinated rabbits. while the control groups
remained negative (Figure 2B–E). Endpoint antibody
titres for the vaccinated groups are shown as geometric
mean titres (GMT) in Supplementary Table S2. The
antibody responses were further boosted after the
second immunization in all groups, while no responses
were detected in the control groups, confirming the
immunogenicity of the tested antigens in rabbits.
Anti-S2 antibody responses were detected in the
HR2 and FP vaccinated groups with weak to no
MERS-CoV neutralizing capacity (Figure 2B,C). Only
HR2 vaccination induced low levels of MERS-CoV
neutralizing antibodies (PRNT90 titres: 20 – 40) in 4/
5 rabbits; all 5 had MERS-CoV neutralizing antibodies
at a 50% cut-off (data not shown).
Likewise, both the monomeric RBD (RBD + LS) and
the multimeric RBD-LS were immunogenic and eli-
cited high S1-specific antibody titres which were
further boosted after the second immunization. The
RBD-LS-induced S1 antibody titres were significantly
higher than those induced by the monomeric RBD fol-
lowing the prime- as well as booster-vaccination (P =
0.0397 and P = 0.0317, respectively by Mann-Whitney
U test) (Figure 2D). Multimeric RBD-LS vaccination
elicited higher MERS-CoV neutralizing antibodies, a
main correlate of protection, than the monomeric
RBD + LS when tested for live virus neutralization
using PRNT90 assay (P = 0.0109, and P = 0.0079,
post-prime and boost, respectively by Mann-Whitney
U test) (Figure 2E). The vaccine induced antibodies
were able to neutralize clade A (EMC/2012 strain;
Figure 2E) as well as the more recently circulating
clade B (Qatar15/2015 strain; Supplementary Figure
S4) viruses. The spike protein of the former strain
differs from the clade A EMC/2012 strain in two pos-
itions; T95S and Q1020R.
Following a single immunization, binding antibody
titres were four-fold higher and neutralizing antibodies
were eleven-fold higher in the coupled multimeric
RBD-LS group than in the uncoupled monomeric
RBD + LS (Supplementary Table S2). Three weeks
after the boost, binding antibody responses were
seven-fold higher (P = 0.0079, Mann-Whitney U test)
and neutralizing antibodies were ten-fold higher (p =
0.0079, Mann-Whitney U test) in the coupled RBD-
LS group than in the uncoupled RBD + LS
(Figure 2D, E Supplementary Table S2). Additionally,
we tested for vaccine induced mucosal immunity in
the respiratory tract of vaccinated rabbits pre-challenge
(Day 49) using ELISA. MERS-CoV specific antibodies
were only detected in the nasal swabs of the groups vac-
cinated with conjugated or non-conjugated RBD
(Figure 2 F,G). Antibody responses detected in the
RBD-LS vaccinated group were higher than those in
the RBD + LS vaccinated group (P = 0.0357, Student’s
t-test). This demonstrates that RBD-LS induces
improved local mucosal immune responses compared
to the monomeric RBD. Thus, vaccination with the
newly produced RBD-LS MERS-CoV MPSP vaccines
induce a robust immune response.
Avidity of RBD-LS induced antibodies
The avidity of MERS-CoV spike-specific antibodies in
the monomeric versus the multimeric RBD vaccinated
groups was analyzed at days 28 (4 weeks after prime)
and 46 (3 weeks after boost) using an ammonium thio-
cyanate (NH4SCN)-displacement ELISA [33]. The
avidity index IC50 was determined for each vaccinated
rabbit and compared between the two groups. The
avidity of the S1-specific antibody responses was higher
following RBD-LS vaccination compared to the mono-
meric RBD + LS vaccination (p < 0.0001, Student’s t-
test) (Figure 3), indicating that a multimeric RBD-LS
vaccine can induce antibody responses of both higher
quantity and quality (Figures 2D,E and 3).
Antibody responses to lumazine synthase
scaffolds
In addition to evaluating anti-S (antigen) responses, we
also tested for the induction on LS-specific (scaffold)
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antibodies. Antibody responses were elicited against
the LS-particle in all groups except the PBS group, indi-
cating that the particle was accessible and not sterically
hidden by antigens displayed on its surface; even when
RBD was displayed on its surface using SpyTag:Spy-
Catcher linkage (Figure 4). Despite that, antigen-
specific responses were not adversely affected by the
presence of these anti-scaffold antibodies, as
demonstrated by the booster effect after the second
immunization (Figure 2D,E). Nonetheless, we tested
whether a heterologous scaffold boost could help in
minimizing such anti-scaffold responses using an LS/
I3 prime-boost scheme. Using this approach, we
found no significant increase in anti-scaffold antibody
responses compared to the homologous prime-boost
scheme (Figure 4C). This indicates that a heterologous
Figure 2. Immunogenicity of MERS-CoV spike MPSP vaccines. (A) Vaccination scheme for rabbit immunizations. Six groups of rab-
bits (5/group) were vaccinated in a prime/boost regimen with 15 μg of adjuvanted vaccine at 4-week interval and challenged with
MERS-CoV (EMC strain; accession no. NC_019843) 3 weeks post-boost. Anti-MERS-CoV spike S2 (B) and S1 (D) IgG titres measured by
ELISA in rabbits at different time points. Shown is the mean ± s.e.m. antibody titres from five rabbits per group. (C,E) MERS-CoV
neutralizing antibody titres measured by a 90% reduction in a plaque reduction neutralization assay (PRNT90). (B-E) Shown is
the mean ± s.e.m. of five rabbits per group. (F,G) Vaccine-induced antibodies in nasal swabs of vaccinated rabbits. Anti MERS-
CoV S2 (F) and S1 (G) antibody responses in the nasal swabs (tested at a 1:50 dilution) of vaccinated rabbits pre-challenge
(three weeks post-boost). The difference in antibody responses between monomeric (RBD + LS) and multimeric (RBD-LS) RBD
was tested for statistical significance using a student’s t-test, with asterisks indicating the level of significance. *P≤ 0.05. Error
bars indicate mean ± s.e.m. The dotted lines represent the limits of detection. HR2, heptad repeat 2; FP, fusion peptide; LS, lumazine
synthase 60-meric particles; I3, I3-01 60-meric particles; RBD, receptor binding domain; RBD + LS, monomeric uncoupled RBD; RBD-
LS, multimeric RBD coupled to LS through covalent SpyTag/SpyCatcher.
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scaffold prime-boost approach could be advantageous
for limiting unnecessary anti-scaffold responses.
Efficacy of RBD-LS in preventing virus shedding
and infection in rabbits
To evaluate the protective efficacy of the immune
responses induced by the different MERS-CoV
spike MPSP vaccines, rabbits were challenged intra-
nasally with 106 TCID50 of MERS-CoV (strain
HCoV-EMC/2012) and nasal swabs were collected
up to 4 days post inoculation (pi) (Figure 2A). On
day 4 pi, the animals were euthanized, and lung tis-
sue samples were collected. Consistent with earlier
reports [34,35], none of the rabbits in the control
group developed any clinical signs of infection
upon MERS-CoV inoculation, and titration of infec-
tious virus from lung tissues and nasal swabs was
variable. Thus, to evaluate protection, we tested for
MERS-CoV RNA by qRT-PCR, for MERS-CoV
infectious virus by virus titration, and for MERS-
CoV antigen (N protein) in lung tissues by immuno-
histochemistry (IHC). Except for the RBD-LS vacci-
nated group, viral RNA was detected in all
vaccinated groups from day 1 through day 4 post-
challenge at levels similar to control groups (Figures
5 and 6). Viral RNA titres were significantly reduced
in the nasal swabs of the RBD-LS vaccinated groups
as early as day 1 post-challenge and were undetect-
able by day 4, in line with the absence of detectable
infectious virus particles (Figure 5). Viral RNA was
also reduced in the lungs of RBD-LS-vaccinated rab-
bits (Figure 6). Consistently, IHC revealed no viral
antigen in the lungs of the RBD-LS vaccinated rab-
bits (Figure 6C), and antigen was also not detected
in the RBD + LS vaccinated rabbits. Overall, in con-
trast to the monomeric form, the antigen-focused
multimeric RBD-LS vaccine was able to block
MERS-CoV replication significantly in the nose and
lungs of the infected rabbits.
Figure 3. Avidity of vaccine-induced serum antibody responses. The avidity of serum IgG antibody responses after one (A, Day 28)
and two immunizations (B, Day 46) with either monomeric RBD (RBD + LS, blue, n = 5) or multimeric RBD (RBD-LS, green, n = 5) was
assessed using ammonium thiocyanate (SCN) avidity ELISA. (A, B) The percentage of serum antibodies bound following the addition
of different concentration of SCN was used to determine (C) the avidity index (IC50). The difference in serum avidity between both
groups was tested for statistical significance using a student’s t-test, with asterisks indicating the level of significance. ***P≤ 0.001,
****P≤ 0.0001. Error bars indicate mean ± s.e.m.
Figure 4. Anti-scaffold antibody responses in sera of vaccinated rabbits. Anti-lumazine synthase (LS) scaffold antibody titres follow-
ing (A) homologous prime boost in monomeric RBD + LS and multimeric RBD-LS vs heterologous LS/I3 prime boost in control LS/I3
as well as (B) HR2-LS/I3 and FP-LS/I3. Shown are (average ± s.e.m. of n = 5 rabbit/group) antibody titres 4 weeks after prime (day 28,
D28) and 3 weeks after boost (day 46, D46) as measured by ELISA. (C) Fold increase (from prime, day 28) in anti-LS antibody titres
following boost vaccination (day 46). A paired t-test was performed to determine significant increases in antibody titres post-prime
and post-boost within groups (A, B), and an unpaired t-test was performed to determine significant changes in titres between
groups (C), with asterisks indicating the level of significance.*P≤ 0.05, **P≤ 0.01, ***P≤ 0.001, ****P≤ 0.0001. The dotted lines
represent the limits of detection. HR2, heptad repeat 2; FP, fusion peptide; LS, lumazine synthase 60-meric particles; I3, I3-01
60-meric particles; RBD, receptor binding domain; RBD + LS, monomeric uncoupled RBD; RBD-LS, multimeric RBD coupled to LS
through covalent SpyTag/SpyCatcher.
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The efficacy of RBD-LS immunization in protecting
against a MERS-CoV challenge, makes it a potential
vaccine candidate. However, for production at indus-
trial scale, unnecessary sequences (e.g. tags) need to
be removed, preparations have to be further structu-
rally and biochemically characterized.
Discussion
Recombinant subunit proteins provide advantages
regarding safety, costs, and speed of vaccine pro-
duction, making them very attractive platforms for
the development of vaccines for emerging viruses.
Multivalent antigen display allows for virus-mimicking
presentation of antigens and has been shown to induce
antibodies of high avidity and magnitude
[7,10,11,27,36]; with non-viral self-assembling MPSP
providing advantages over other multimeric antigen
presentation platforms [8,12]. Among the MERS-
CoV vaccine candidates developed so far, the latter
approach has been used to design two candidates,
both are based on the receptor-binding domain
[27,37], the main target for MERS-CoV protective anti-
bodies [26]. One used self-assembling ferritin nanopar-
ticles [27] and the second used canine parvovirus
(CPV) VP2 structural protein forming virus like par-
ticles [37] as scaffolds. Both vaccine candidates were
able to induce humoral and cellular immune responses
in mice, nonetheless none has been tested for its pro-
tective capacity in a viral-challenge animal model. In
our study, using an immune-focusing approach to tar-
get protective epitopes and domains along with multi-
valent presentation on self-assembling LS particles
using a spontaneous covalent linker (SpyTag/Spy-
Catcher). We report for the first time the in-vivo pro-
tective capacity of a multimeric MERS-CoV RBD
particle vaccine.
We used self-assembling LS and I3 particles to gen-
erate chimeric multimeric protein scaffold particle dis-
playing critical domains in the MERS-CoV spike
protein and evaluated their immunogenicity and pro-
tective efficacy in rabbits. Multimeric FP and HR2 vac-
cinations induced high levels of anti-S2 antibodies,
nonetheless, with low to undetectable virus neutraliz-
ing capacities and couldn’t protect rabbits against
virus challenge. Meanwhile, multimeric RBD-LS vacci-
nation was highly immunogenic and induced robust
antibody responses of high magnitude, avidity and
neutralizing capacity. Following a live virus challenge,
it protected upper and lower respiratory tract of rabbits
as detected by decrease in viral RNA titres, with an
associated lack of MERS-CoV antigen (Figures 5 and
6). Despite producing strong antibody responses, the
monomeric RBD failed to protect rabbits against
MERS-CoV following an intranasal challenge. The
presence of LS did not seem to influence the outcome,
Figure 5. Protective capacity of MERS-CoV MPSP vaccines against upper respiratory tract infection in rabbits. Six groups of vacci-
nated and control rabbits (n = 5/group) were tested for the presence of viral RNA (A, C) and infectious virus particles (B, D) in the
upper respiratory tract (nasal swabs) at days −3 and 1–4 post intranasal viral challenge (days 46 and 50–53 post first vaccination)
with 106 TCID50 MERS-CoV EMC strain. Shown is the average ± s.e.m. of five animals per group. The dotted lines represent the limits
of detection. HR2, hepad repeat 2; FP, fusion peptide; LS, lumazine synthase 60-meric particles; I3, I3-01 60-meric particles; RBD,
receptor binding domain; RBD + LS, monomeric uncoupled RBD; RBD-LS, multimeric RBD coupled to LS through covalent Spy-
Tag/SpyCatcher.
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as it was included in the formulation of the monomeric
form (RBD + LS), indicating that the coupling and the
multimeric presentation are responsible for the
enhanced response seen with the multimeric RBD-LS
vaccine. The “plug-and-display” SpyTag/SpyCatcher
system [8] used to generate these multimeric RBD-LS
particles allows for rapid and robust production of vac-
cines in a cost-effective manner. This enables the devel-
opment of vaccines in a timely manner, which is crucial
to prevent global public health consequences of evol-
ving, emerging and re-emerging viruses.
The efficacy of RBD-LS immunization in protecting
against a MERS-CoV challenge, makes it a potential
vaccine candidate for further development. Nonethe-
less, in case of production at an industrial scale,
unnecessary sequences (e.g. tags) need to be removed,
preparations have to be further structurally and bio-
chemically characterized.
When using scaffolds as antigen carriers, anti-scaffold
antibody responses need to be considered to avoid their
potential to compromise the targeted antigen-induced
responses or to induce potential auto-antibodies against
human antigens. Antibody responses were induced
against the LS protein scaffold used in this study. How-
ever, antigen-specific responses were boosted following
the second immunization and were not adversely
affected by the presence of these anti-scaffold antibodies
(Figure 4), similar to other reports [38]. Since the
sequence of the LS protein does not show any similarity
to any human sequences, it is unlikely that they will
induce unwanted auto- (antihuman) antibodies. An
LS-based vaccine for HIV, in a current phase 1 clinical
trial (NCT03547245), can provide further evidence for
the safety of this platform. Nonetheless, we developed
a heterologous scaffold prime-boost using LS and I3
which can help in reducing anti-scaffold responses.
A challenge facing MERS-CoV vaccine development
is the limited number of appropriate animal models for
testing protection against clinical virus isolates. Rabbits
provide some advantages as an animal model for
MERS-CoV. By having the MERS-CoV receptor
DPP4 expressed in both the upper and lower respirat-
ory tract epithelium [24], the rabbits can be naturally
infected. This allows the evaluation of both upper
and lower respiratory tract MERS-CoV infection and
in turn protection using natural field virus isolates
rather than adapted strains. However, the animals are
not able to develop severe infection such as that seen
in severe human cases [34]. Nonetheless, severe infec-
tion, thus far, has not been established consistently in
any of the other animal models without genetic modifi-
cation and/or virus adaptation, except for marmosets
[39]. In addition to the aforementioned, rabbits are
readily available and easier to handle compared to
other species that can be naturally infected such as
non-human primates.
Following the addition of MERS-CoV as a priority
pathogen in the WHO R&D Blueprint for action to
prevent epidemics, a target product profile was devel-
oped which called for three types of MERS-CoV vac-
cines [40]. These include one for camels to prevent
virus shedding and transmission, and two for humans:
Figure 6. Protective capacity of MERS-CoV MPSP vaccines
against lower respiratory tract infection in rabbits. Six groups
of vaccinated and control rabbits (n = 5/group) were tested
for the presence of viral RNA (A, B) in the lung tissue homogen-
ates and viral nucleocapsid antigen in lung tissues (C) collected
4 days post intranasal viral challenge with 106 TCID50 of MERS-
CoV (EMC isolate). (A, B) Shown are the average and SEM equiv-
alent virus titres/gram of tissue. C) Representative pictures of
immunohistochemical detection of MERS-CoV nucleoprotein
(shown in red) in the lungs of PBS (left) vs RBD-LS (right) immu-
nized rabbits four days post-viral challenge; the upper and
lower panels show a 200X and 1000X magnification, respect-
ively. HR2, hepad repeat 2; FP, fusion peptide; LS, lumazine
synthase 60-meric particles; I3, I3-01 60-meric particles; RBD,
receptor binding domain; RBD + LS, monomeric uncoupled
RBD; RBD-LS, multimeric RBD coupled to LS through covalent
SpyTag/SpyCatcher.
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a two-dose vaccine for long-term protection of those at
continuous high risk such as camel handlers and
health-care workers, and a single-dose vaccine for
rapid onset of immune responses to protect those at
acute risk in outbreak settings. The RBD-LS can be
used to develop the two-dose vaccine required to pro-
tect the high-risk populations, and can be further opti-
mized using the heterologous scaffold prime/boost
scheme developed in this study. Nonetheless, evaluat-
ing the longevity of the induced immune responses is
warranted. Following the prime, RBD-LS vaccination
induced antibody responses of high avidity and
MERS-CoV neutralizing capacity. Owing to the robust
immune responses induced after one dose, the RBD-LS
can be a candidate for developing a rapid single-dose
vaccine for MERS-CoV, which is required for reactive
use in outbreak situations [40]. Additionally, this vac-
cine candidate was able to block MERS-CoV replica-
tion in the upper respiratory tract of infected rabbit,
thus it could potentially be of use as a dromedary vac-
cine to block MERS-CoV transmission. However, both
approaches need to be further validated.
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